- Home
- RVYL vs PHIO Comparison
RVYL vs PHIO Comparison
Compare RVYL & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVYL
- PHIO
- Stock Information
- Founded
- RVYL 2007
- PHIO 2011
- Country
- RVYL United States
- PHIO United States
- Employees
- RVYL N/A
- PHIO N/A
- Industry
- RVYL Professional Services
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- RVYL Consumer Discretionary
- PHIO Health Care
- Exchange
- RVYL Nasdaq
- PHIO Nasdaq
- Market Cap
- RVYL 10.3M
- PHIO 11.9M
- IPO Year
- RVYL N/A
- PHIO N/A
- Fundamental
- Price
- RVYL $0.66
- PHIO $2.32
- Analyst Decision
- RVYL Hold
- PHIO Strong Buy
- Analyst Count
- RVYL 1
- PHIO 2
- Target Price
- RVYL N/A
- PHIO $9.00
- AVG Volume (30 Days)
- RVYL 779.0K
- PHIO 200.0K
- Earning Date
- RVYL 08-12-2025
- PHIO 08-13-2025
- Dividend Yield
- RVYL N/A
- PHIO N/A
- EPS Growth
- RVYL N/A
- PHIO N/A
- EPS
- RVYL N/A
- PHIO N/A
- Revenue
- RVYL $54,357,000.00
- PHIO N/A
- Revenue This Year
- RVYL $27.50
- PHIO N/A
- Revenue Next Year
- RVYL $35.71
- PHIO N/A
- P/E Ratio
- RVYL N/A
- PHIO N/A
- Revenue Growth
- RVYL N/A
- PHIO N/A
- 52 Week Low
- RVYL $0.36
- PHIO $0.97
- 52 Week High
- RVYL $2.40
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- RVYL 43.93
- PHIO 55.02
- Support Level
- RVYL $0.60
- PHIO $2.33
- Resistance Level
- RVYL $0.75
- PHIO $2.62
- Average True Range (ATR)
- RVYL 0.10
- PHIO 0.15
- MACD
- RVYL -0.01
- PHIO 0.00
- Stochastic Oscillator
- RVYL 7.89
- PHIO 65.69
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.